Navigation Links
New Tel Aviv University research links diabetes to cognitive deterioration
Date:3/5/2009

Blindness, renal failure, stroke and heart disease are potential complications of type 2 diabetes, which currently afflicts more than 15 million Americans. Now research from Tel Aviv University has found more worrying news ― type 2 diabetes can be a risk factor accelerating cognitive decline and dementia.

Dr. Tali Cukierman-Yaffe, a physician and researcher from TAU's Sackler School of Medicine, found that people with diabetes were 1.5 more likely to experience cognitive decline, and 1.6 more likely to suffer from dementia than people without diabetes. Her recent publication in the journal Diabetes Care suggests that higher-than-average levels of blood glucose (blood sugar) may have a role in this relationship.

Her work is part of the ongoing Memory in Diabetes (MIND) project, a sub-study of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

First Step Towards New Treatments

"Our results send an important message to the public," says Dr. Cukierman-Yaffe. "We have shown conclusively that there is a relationship between diabetes and cognitive dysfunction. This should be known by diabetics and their doctors. Knowledge is the first step towards action.

"Intact thinking is essential for managing the disease," Dr. Cukierman-Yaffe adds.

Clinicians today work with the patient to prevent complications of diabetes. Early detection of visual problems, for example, can be treated with laser surgery if diagnosed early enough, and blindness can be avoided in some cases.

"Today, diabetes cannot be cured. We can however delay or prevent many of its complications," says Dr. Cukierman-Yaffe. "Diagnosing cognitive dysfunction at a pre-clinical stage is the first step in finding new treatment options."

A New Association with Poor Cognitive Performance

Dr. Cukierman-Yaffe's work opens a new opportunity for researchers to better understand the cognitive risks associated with diabetes and dysglycemia. She points out that diabetes, unlike other chronic disease states, is a complex disease to manage and one that requires intact cognition in the patient. As the mind starts deteriorating, so does the patient's ability to treat the diabetes effectively. Disease management can then spiral out of control.

Findings in her recent study show that in people with type 2 diabetes, higher levels of haemoglobin A1C (a measure of average blood glucose) are significantly associated with poorer performance on three cognitive tasks which require memory, speed and ability to manage multiple tasks at the same time. A higher A1C level was also associated with a lower score on a test of global cognitive function.

The results of the study suggest that lowering A1C levels could slow the accelerated rate of cognitive decline experienced by people with diabetes. However prospective studies and clinical trials are needed in order to prove this. The ongoing ACCORD-MIND study, in which study patients are followed over time and are tested three times during the trial will test the hypothesis that lowering A1C could result in improved cognitive function.


'/>"/>

Contact: George Hunka
ghunka@aftau.org
212-742-9070
American Friends of Tel Aviv University
Source:Eurekalert

Related medicine news :

1. University of Iowa professor identifies new eating disorder
2. University of Wisconsin Hospitals and Clinics Complete System-Wide Conversion to Masimo SET Pulse Oximetry Technology
3. University of Texas Study Details Lengthy Payment Delays for Medicare Part D Prescription Drug Claims, Confirming Need for Legislative Fix
4. Tulane University to receive $14M for international HIV/AIDS program
5. University of Nevada School of Medicine Professor Confirms Accuracy Through Validation Study Using the CSI Health Station Model 6K
6. Boston University School of Medicine researcher recipient of Memory Ride Grant
7. Loma Linda University Medical Center Selects Beryl to Manage Call Center Interactions for Womens Services Programs and Departments
8. Medina General Hospital and University Hospitals Agree to Pursue Affiliation
9. J.D. Power and Associates Reports: Hackensack University Medical Center Recognized as First Hospital to Achieve Distinction for Providing an Outstanding Inpatient Experience in All Four Service Areas
10. The First Incisionless Transoral Fundoplication for Treatment of Gastroesophageal Reflux is Performed in the U.S. at Ohio State University and Oregon Health & Science University Medical Centers
11. George Mason University professor receives $2.6 million NIH grant to study Alzheimers disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... January 23, 2017 , ... Gynecology ... care and gynecological services for women of all ages. The staff ... wide variety of reproductive services from routine health screenings to diagnosing and treating ...
(Date:1/23/2017)... ... ... “Crossing the Bar”: a moving and eloquent drama depicting the events ... is the creation of published author, Charlotte Hotte, a North Carolina native, a mother ... of the book to her sister, Denise, wishes to acknowledge her savior, Jesus Christ, ...
(Date:1/23/2017)... ... January 23, 2017 , ... “Life Under Blankets”: an entrancing ... early age. “Life Under Blankets” is the creation of published author, Kimberly Mitchell, who ... in Chicago. She went on to pursue a master’s degree in education in the ...
(Date:1/23/2017)... , ... January 23, 2017 , ... Valentine’s Day is a time when many people ... ones. For those who may be looking for the ideal present, Atlanta-based Perimeter Plastic ... get an additional $25 free. Or, spend $200 and get $50 free. , “A ...
(Date:1/22/2017)... ... January 22, 2017 , ... Zifam Pinnacle, an Australian company dedicated to providing ... big-name retail buyers at the January ECRM Trade Show in Hilton Head, SC. , ... safety standards in all of its creations to help create a more traditional and ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... , Jan. 20, 2017 ARMO BioSciences, Inc., ... data on the Company,s lead investigational immuno-oncology drug AM0010 ... by the American Society of Clinical Oncology (ASCO), taking ... CA. "AM0010 induces the ... + T cells in the blood and tumors ...
(Date:1/20/2017)... -- Research and Markets has announced the addition ... BMP, BUN Creatinine, Electrolyte Testing, HbA1c Testing, Comprehensive Metabolic Panel, Liver ... - 2024" report to their offering. ... The global clinical laboratory testing market ... Introduction of innovative solutions on the grounds of maximum efficiency and ...
(Date:1/20/2017)... Research and Markets has announced the addition of ... report to their offering. ... This research service on the global pharmaceutical stability ... a snapshot of the key participants in the market. ... 2016 to 2020. The market is expected to grow at a ...
Breaking Medicine Technology: